Testing effectiveness (Phase 2)UnknownNCT02504346
What this trial is testing
AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies
Who this might be right for
Lung CancerTargeted Therapy
Oslo University Hospital 200